Drug intelligence / Profile preview

Lepticur

Development stage: Unknown
Lead developer: Laboratoires Delbert
Modality: Small Molecules
Administration: Oral, Intramuscular, Intravenous

Overview

Lepticur (tropatepine hydrochloride) is a muscarinic anticholinergic agent indicated for the treatment of neurological disorders involving extrapyramidal symptoms. Specifically, it is used for the initial emergency correction of acute extrapyramidal manifestations induced by neuroleptics, such as parkinsonian syndromes. Developed originally by Sanofi and currently marketed by Delbert Pharma, the drug acts as an antimuscarinic agent with a notably long half-life of approximately 40 hours. It is available in both oral tablet and injectable solution formulations, making it suitable for both acute emergency use and maintenance therapy.

Brand names: Lepticur
Other names: tropatepinetropatepine hydrochloride

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Lepticur.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lepticur.

Explore the full profile